How should a suspected resistant infection be evaluated and managed?

Tinea Corporis Resistant: Evaluation and Management

When tinea corporis fails standard antifungal therapy, obtain fungal culture with susceptibility testing and consider dermatophyte identification to guide targeted systemic therapy, as resistance patterns vary by species and geographic region.

Initial Evaluation of Suspected Resistant Infection

Clinical Assessment

• Duration and adequacy of prior therapy: Verify the patient completed at least 2-4 weeks of appropriate topical therapy with adequate application technique
• Confirm the diagnosis: Rule out mimickers including nummular eczema, psoriasis, granuloma annulare, or bacterial infections (especially if pustular features present)
• Identify risk factors for resistance:
  • Immunosuppression (HIV, diabetes, chronic corticosteroid use)
  • Previous antifungal exposure
  • Geographic origin from areas with known resistant dermatophyte prevalence
  • Close contact with animals or contaminated environments

Diagnostic Workup

Obtain specimens before initiating systemic therapy:

• KOH preparation: Immediate confirmation of fungal elements
• Fungal culture: Essential for species identification and susceptibility testing
  • Collect scale from active border using sterile scalpel blade
  • Submit adequate specimen volume in appropriate transport medium
  • Request dermatophyte identification to species level
• Consider dermatopathology: If diagnosis uncertain or atypical presentation suggests deep fungal infection

Management Algorithm

Step 1: Optimize Topical Therapy First

Before assuming resistance, ensure:

• Adequate treatment duration (minimum 2 weeks beyond clinical clearing)
• Appropriate vehicle and concentration
• Treatment of all affected sites including subclinical extension
• Address contributing factors (moisture, occlusion, continued exposure)

Step 2: Systemic Antifungal Therapy

For confirmed resistant or refractory tinea corporis:

First-line systemic options:

• Terbinafine 250 mg daily for 2-4 weeks: Most effective for dermatophytes, fungicidal mechanism
• Itraconazole 200 mg daily for 2-4 weeks: Alternative if terbinafine contraindicated or ineffective
• Fluconazole 150-300 mg weekly for 4-6 weeks: Consider for Candida co-infection

Adjust based on culture results:

• If Trichophyton rubrum with terbinafine resistance documented: Switch to itraconazole or fluconazole
• If Trichophyton mentagrophytes complex: May require higher doses or longer duration
• If Microsporum canis: Griseofulvin may be more effective (20-25 mg/kg/day for 4-6 weeks)

Step 3: Combination Therapy

For severe or persistent cases despite monotherapy:

• Systemic antifungal PLUS topical antifungal (different class)
• Consider adding topical keratolytic (salicylic acid) to enhance penetration
• Address any underlying immunosuppression

Step 4: Refractory Cases

If failure after 6-8 weeks of appropriate systemic therapy:

• Repeat culture and susceptibility testing: Resistance patterns may evolve
• Consider alternative diagnoses: Deep fungal infection, atypical mycobacterial infection
• Infectious disease consultation: For complex or immunocompromised patients
• Investigate environmental sources: Treat household contacts, decontaminate fomites

Critical Pitfalls to Avoid

1. Starting systemic therapy without culture: You cannot confirm resistance or guide therapy without microbiologic data
2. Inadequate treatment duration: Dermatophyte infections require treatment beyond clinical clearing to prevent relapse
3. Missing drug interactions: Azoles have significant CYP450 interactions; review medication list carefully
4. Ignoring the source: Failure to address reinfection from pets, contaminated clothing, or household contacts leads to recurrence
5. Assuming all treatment failures are resistance: Poor adherence, inadequate dosing, and misdiagnosis are more common than true resistance

Monitoring and Follow-up

• Clinical assessment at 2-4 weeks: Expect improvement but not complete clearing
• Repeat culture if no improvement: Confirms persistent infection versus slow response
• Monitor for adverse effects: Hepatotoxicity with systemic azoles and terbinafine (baseline and follow-up LFTs if treatment >4 weeks)
• Document clearance: Clinical and mycological cure before discontinuing therapy

Special Considerations

True antifungal resistance in dermatophytes remains uncommon but is emerging, particularly with Trichophyton indotineae (formerly T. mentagrophytes genotype VIII) showing multi-azole resistance. This organism has been reported with increasing frequency in South Asia and is spreading globally. If suspected based on geographic exposure or multiple treatment failures, aggressive combination therapy and infectious disease consultation are warranted.

The distinction between treatment failure due to resistance versus inadequate therapy, poor penetration, or continued reinfection is critical and can only be made with proper microbiologic evaluation.